Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | Mkt Perform | Raymond James | |
| 7/17/2024 | $344.00 → $392.00 | Buy | Lake Street |
| 3/20/2024 | Market Outperform | CJS Securities | |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 12/21/2022 | $124.00 | Buy | Lake Street |
| 6/22/2022 | $110.00 | Buy | Lake Street |
| 11/19/2021 | $81.00 | Buy | Colliers Securities |
Raymond James initiated coverage of UFP Technologies with a rating of Mkt Perform
Lake Street reiterated coverage of UFP Technologies with a rating of Buy and set a new price target of $392.00 from $344.00 previously
CJS Securities initiated coverage of UFP Technologies with a rating of Market Outperform
NEWBURYPORT, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly and Chief Financial Officer Ron Lataille will participate in the upcoming Raymond James 47th Annual Institutional Investors Conference to be held in Orlando, Florida March 1-4, 2026. UFP's presentation is scheduled to begin at 2:50 PM on Tuesday, March 3rd. A live webcast of UFP's presentation will be available here. About UFP Technologies, Inc.UFP Technologies is a contract development and manufacturing
NEWBURYPORT, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported 2025 net income of $68.3 million, 15.8% higher than net income of $59.0 million for 2024. Adjusted net income grew 12.7% to $76.1 million. Net sales for the year ended December 31, 2025 were $602.8 million, 19.5% higher than 2024 sales of $504.4 million. GAAP and adjusted earnings per diluted common share outstanding ("EPS") for the year ended December 31, 2025 were $8.75 and $9.76, respectively. Throughout this news release, reference is made to non-GAAP measures
NEWBURYPORT, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the fourth quarter and year-end on Tuesday, February 24th, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, February 25th, at 8:30 AM Eastern time. Conference Call Information:Date: Wednesday, February 25, 2026Time: 8:30 AM Eastern Time Participants may join the call using the following dial-in numbers: USA/Canada: Toll-Free: 1-412-206-6478Intern
10-K - UFP TECHNOLOGIES INC (0000914156) (Filer)
8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)
8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)
NEWBURYPORT, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of AQF Limited ("AQF Medical"). Headquartered in Navan, Ireland with additional joint venture operations in Singapore, AQF Medical develops and manufactures custom-engineered foam and thermoplastic components used in a wide range of medical devices and packaging. "We are excited about the addition of AQF Medical, our fourth acquisition in the past few months," said R. Jeffrey Bailly, Chairman and CEO of UFP Technologies.
NEWBURYPORT, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of Marble Medical. Founded in 1988 and headquartered in Tallahassee, FL, Marble Medical develops and manufactures adhesive based medical components and single-use devices. "Adding Marble Medical's adhesives expertise is a great complement to our surgical robot drapes and stick to skin device platforms," said R. Jeffrey Bailly, chairman and CEO of UFP Technologies. "Marble Medical is a 3M Preferred Converter, and along wi
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo
SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)
SC 13G/A - UFP TECHNOLOGIES INC (0000914156) (Subject)
SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)
NEWBURYPORT, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported 2025 net income of $68.3 million, 15.8% higher than net income of $59.0 million for 2024. Adjusted net income grew 12.7% to $76.1 million. Net sales for the year ended December 31, 2025 were $602.8 million, 19.5% higher than 2024 sales of $504.4 million. GAAP and adjusted earnings per diluted common share outstanding ("EPS") for the year ended December 31, 2025 were $8.75 and $9.76, respectively. Throughout this news release, reference is made to non-GAAP measures
NEWBURYPORT, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the fourth quarter and year-end on Tuesday, February 24th, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, February 25th, at 8:30 AM Eastern time. Conference Call Information:Date: Wednesday, February 25, 2026Time: 8:30 AM Eastern Time Participants may join the call using the following dial-in numbers: USA/Canada: Toll-Free: 1-412-206-6478Intern
NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per dilute